Pages that link to "Q35171276"
Jump to navigation
Jump to search
The following pages link to Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot study (Q35171276):
Displayed 50 items.
- Putting together the psoriasis puzzle: an update on developing targeted therapies (Q27026785) (← links)
- Psoriasis and comorbid diseases: Epidemiology (Q30235889) (← links)
- Management of cardiovascular disease in patients with psoriasis (Q30250278) (← links)
- The Role of IL-17 in the Pathogenesis and Treatment of Psoriasis (Q33574671) (← links)
- Vascular inflammation in psoriasis localizes to the arterial wall using a novel imaging technique (Q33624882) (← links)
- Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2014 MauiDerm Meeting (Q34377347) (← links)
- Accumulating evidence for the association and shared pathogenic mechanisms between psoriasis and cardiovascular-related comorbidities (Q34434622) (← links)
- Psoriatic arthritis and sacroiliitis are associated with increased vascular inflammation by 18-fluorodeoxyglucose positron emission tomography computed tomography: baseline report from the Psoriasis Atherosclerosis and Cardiometabolic Disease Initia (Q34668556) (← links)
- IL-17A production in human psoriatic blood and lesions by CD146+ T cells (Q34714063) (← links)
- Psoriasis and Cardiovascular Risk: Strength in Numbers Part 3 (Q35962417) (← links)
- Assessing Cutaneous Psoriasis Activity Using FDG-PET: Nonattenuation Corrected Versus Attenuation Corrected PET Images. (Q36108233) (← links)
- Chronic skin-specific inflammation promotes vascular inflammation and thrombosis (Q36110025) (← links)
- Increased 18F-FDG uptake suggests synovial inflammatory reaction with osteoarthritis: preliminary in-vivo results in humans. (Q36225333) (← links)
- The impact of psoriasis on 10-year Framingham risk (Q36240763) (← links)
- Quantification of atherosclerotic plaque activity and vascular inflammation using [18-F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT). (Q36305268) (← links)
- Severity of Psoriasis Associates With Aortic Vascular Inflammation Detected by FDG PET/CT and Neutrophil Activation in a Prospective Observational Study (Q36326833) (← links)
- Chronic Psoriatic Skin Inflammation Leads to Increased Monocyte Adhesion and Aggregation (Q36390768) (← links)
- Aortic vascular inflammation in psoriasis is associated with HDL particle size and concentration: a pilot study (Q36404574) (← links)
- Characterization of Lipoprotein Composition and Function in Pediatric Psoriasis Reveals a More Atherogenic Profile. (Q36514727) (← links)
- Metabolic syndrome in patients with psoriatic disease. (Q36897095) (← links)
- Increased risk of diabetes mellitus and likelihood of receiving diabetes mellitus treatment in patients with psoriasis (Q36914874) (← links)
- Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis (Q36957991) (← links)
- The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses (Q37040371) (← links)
- Modulation of cardiometabolic pathways in skin and serum from patients with psoriasis (Q37152902) (← links)
- Feasibility of carotid artery PET/MRI in psoriasis patients (Q37215507) (← links)
- Psoriasis severity and the prevalence of major medical comorbidity: a population-based study (Q37239394) (← links)
- A comparison of vascular inflammation in psoriasis, rheumatoid arthritis, and healthy subjects by FDG-PET/CT: a pilot study (Q37285410) (← links)
- Perioperative stroke in a patient undergoing surgery for oral cancer: A case report (Q37287455) (← links)
- Psoriasis is associated with decreased plasma adiponectin levels independently of cardiometabolic risk factors. (Q37405750) (← links)
- High-density lipoprotein cholesterol function improves after successful treatment of psoriasis: a step forward in the right direction (Q37593287) (← links)
- Endothelial cell-, platelet-, and monocyte/macrophage-derived microparticles are elevated in psoriasis beyond cardiometabolic risk factors. (Q37648544) (← links)
- Psoriasis and Psoriatic Arthritis (Q37723047) (← links)
- Does treatment of psoriasis reduce the risk of cardiovascular disease? (Q38178202) (← links)
- Impact of smoking on response to systemic treatment in patients with psoriasis: a retrospective case-control study (Q38241734) (← links)
- Impact of systemic inflammation and autoimmune diseases on apoA-I and HDL plasma levels and functions (Q38293477) (← links)
- The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events (Q38615718) (← links)
- The Link Between Inflammatory Disorders and Coronary Heart Disease: a Look at Recent Studies and Novel Drugs in Development (Q38688816) (← links)
- Psoriasis as a human model of disease to study inflammatory atherogenesis (Q39160397) (← links)
- Systemic immune mechanisms in atopic dermatitis and psoriasis with implications for treatment (Q39165518) (← links)
- Neutrophil-to-lymphocyte ratio may predict subclinical atherosclerosis in patients with psoriasis (Q39267608) (← links)
- Cardiometabolic Disorders in Psoriatic Disease (Q40069191) (← links)
- A Patient with Psoriatic Arthritis Imaged with FDG-PET/CT Demonstrated an Unusual Imaging Pattern with Muscle and Fascia Involvement: A Case Report (Q40219226) (← links)
- GlycA Is a Novel Biomarker of Inflammation and Subclinical Cardiovascular Disease in Psoriasis. (Q40571559) (← links)
- IL-17 Blockade in Psoriasis: Friend or Foe in Cardiovascular Risk? (Q41104626) (← links)
- The prevalence of NAFLD and NASH among patients with psoriasis in a tertiary care dermatology and rheumatology clinic (Q41673511) (← links)
- Advances in psoriasis treatment: experts comment on recent developments (Q41833324) (← links)
- Psoriasis and Cardiovascular Comorbidities: Focusing on Severe Vascular Events, Cardiovascular Risk Factors and Implications for Treatment (Q46180528) (← links)
- Comorbidities, metabolic risk profile and health-related quality of life in German patients with plaque-type psoriasis: a cross-sectional prospective study (Q46625469) (← links)
- The role of weight loss in the treatment of psoriasis: evidence that psoriasis is a systemic inflammatory disorder linked to metabolic syndrome (Q47179309) (← links)
- Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis (Q47218445) (← links)